Anaplastic Large Cell Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone | FDA |
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin | FDA |
| Sensitivity (+) | v::ALK | Anaplastic Large Cell Lymphoma | Crizotinib | FDA |
| Sensitivity (+) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone | HC |